Saleh et al. [50] reported that p53 gene mutations are very frequent in high-grade serous ovarian cancer (HGSC), while the frequency of p53 mutations in normal organs is relatively low, making p53 an attractive target for specific therapy of HGSC. The gene discussed is TP53; the disease is ovarian serous adenocarcinoma.